Overview

Colchicine in Percutaneous Coronary Intervention

Status:
Active, not recruiting
Trial end date:
2024-08-30
Target enrollment:
Participant gender:
Summary
Inflammation in the arteries of the heart may increase the risk of cardiac death. The proposed research seeks to identify the potential beneficial role of a safe anti-inflammatory medication, colchicine, on reducing damage caused by opening up a blockage in the arteries of the heart. With its quick onset of action and excellent safety profile, colchicine may have the potential to reduce risk of major adverse events related to the heart. This research also seeks to better understand the role of neutrophils, the most common type of inflammatory white blood cell in the body, when there is damage to the heart.
Phase:
Phase 4
Details
Lead Sponsor:
VA Office of Research and Development
Collaborators:
New York University School of Medicine
NYU Langone Health
Treatments:
Colchicine